When does the dolutegravir patent expire?
The exact patent expiration date for dolutegravir depends on the specific patent(s) covering the drug in a given country and whether any extensions (such as patent term adjustments or supplementary protection certificates) apply. Patent rights are granted and enforced country-by-country, so there is no single global expiration date.
In practice, people looking for a “dolutegravir patent expiration date” usually need to identify:
the country (e.g., US, EU, India), and
the specific patent family and jurisdictional filing that protects dolutegravir in that market.
How do you find the patent expiration date for dolutegravir in the country you care about?
Start with a regulator or patent database query for “dolutegravir” and then match the results to:
the relevant patent numbers (or patent family) for the market, and
the jurisdiction (because expiration dates vary across countries), and
any listed patent term extensions in that jurisdiction.
If you tell me which country (and, if relevant, the brand/product you mean), I can help you narrow down what to look for and how to interpret the expiration/expiry data.
Does dolutegravir face multiple patent-expiration dates (not one)?
Yes. Dolutegravir can be covered by different types of patents, which can expire at different times, such as:
composition-of-matter (covering the drug itself), and
process/synthesis patents, and
formulation, salt, or fixed-dose combination patents (e.g., when dolutegravir is used with other antiretrovirals).
That means even if one patent expires, other patents may still block or delay generic or biosimilar entry for certain specific products or combinations.
Can generics enter before all dolutegravir patents expire?
Often the answer is “sometimes, for some products.” Generic manufacturers typically look for a path that avoids active patents in the relevant jurisdiction. But entry timing can be affected by:
which patent(s) are still in force,
whether regulators approve the generic while litigation is ongoing, and
whether there are market exclusivities or other regulatory barriers tied to the specific product.
What are the biggest reasons the “expiration date” you find online might not match the real situation?
Common mismatches include:
mixing up different countries’ expiration dates,
confusing application publication dates with granted patent term,
ignoring patent term extensions or adjustments,
and not accounting for separate patents covering different fixed-dose combinations or formulations.
Which dolutegravir product or combination do you mean?
Dolutegravir is sold in multiple products and fixed-dose combinations (depending on country). Patent-expiration outcomes can differ by:
the exact drug combination in the product (for example, dolutegravir-only vs fixed-dose combos), and
the formulation (if a specific formulation is patented separately).
If you share the country and the specific product/brand (or whether you mean dolutegravir alone vs a fixed-dose combination), I can tailor the “patent expiration date” search to the right jurisdiction and patent set.